Compare HAS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAS | PRME |
|---|---|---|
| Founded | 1923 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 536.4M |
| IPO Year | 1994 | 2022 |
| Metric | HAS | PRME |
|---|---|---|
| Price | $80.50 | $3.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $109.73 | $7.56 |
| AVG Volume (30 Days) | 1.8M | ★ 3.4M |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $5,365,900,000.00 | $4,632,000.00 |
| Revenue This Year | $5.38 | $7.06 |
| Revenue Next Year | $6.48 | $47.01 |
| P/E Ratio | $57.60 | ★ N/A |
| Revenue Growth | 13.06 | ★ 55.28 |
| 52 Week Low | $69.50 | $2.67 |
| 52 Week High | $106.98 | $6.94 |
| Indicator | HAS | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 33.51 | 65.67 |
| Support Level | $79.45 | $3.16 |
| Resistance Level | $84.30 | $4.04 |
| Average True Range (ATR) | 1.97 | 0.29 |
| MACD | -0.01 | 0.10 |
| Stochastic Oscillator | 6.05 | 71.15 |
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to 19 million digital tabletop players.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.